Mechanism by Which Mutations at His274 Alter Sensitivity of Influenza A Virus N1 Neuraminidase to Oseltamivir Carboxylate and Zanamivir
Open Access
- 1 December 2002
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 46 (12), 3809-3816
- https://doi.org/10.1128/aac.46.12.3809-3816.2002
Abstract
Oseltamivir carboxylate is a potent and specific inhibitor of influenza neuraminidase (NA). An influenza A/H1N1 variant selected in vitro with reduced susceptibility to oseltamivir carboxylate contains a His274Tyr mutation. To understand the mechanism by which a His274Tyr mutation gives rise to drug resistance, we studied a series of NA variant proteins containing various substitutions at position 274. Replacement of His274 with larger side chain residues (Tyr or Phe) reduced the NA sensitivity to oseltamivir carboxylate. In contrast, replacement of His274 with smaller side chain residues (Gly, Asn, Ser, and Gln) resulted in enhanced or unchanged sensitivity to oseltamivir carboxylate. Previous studies have suggested that the slow-binding inhibition of NA by oseltamivir carboxylate is a result of the reorientation of Glu276. Loss of this slow-binding inhibition in the His274Tyr and His274Phe mutant NA but not in His274Asn, His274Gly, His274Ser, or His274Gln supports the conclusion that the conformational change of Glu276 is restricted in the His274Tyr and His274Phe mutant NA upon oseltamivir carboxylate binding. Interestingly, His274Asn, as well as His274Gly, His274Ser, and His274Gln, also displayed reduced sensitivity to zanamivir and its analogue, 4-amino-Neu5Ac2en. Substitution of His274 with Tyr in influenza A/Tokyo/3/67 (H3N2) recombinant NA did not affect the susceptibility to oseltamivir carboxylate. These data indicate that the volume occupied by the amino acid side chain at position 274 can influence the sensitivities of influenza N1 NA but not of N2 NA to both oseltamivir carboxylate and zanamivir.Keywords
This publication has 54 references indexed in Scilit:
- Selection of Influenza Virus Mutants in Experimentally Infected Volunteers Treated with OseltamivirThe Journal of Infectious Diseases, 2001
- Anti-viral drug resistanceJournal of Clinical Virology, 2000
- Use of the Selective Oral Neuraminidase Inhibitor Oseltamivir to Prevent InfluenzaNew England Journal of Medicine, 1999
- Disarming Flu VirusesScientific American, 1999
- Targeting influenza virus neuraminidase—a new strategy for antiviral therapyDrug Discovery Today, 1998
- A Study of the Active Site of Influenza Virus Sialidase: An Approach to the Rational Design of Novel Anti-influenza DrugsJournal of Medicinal Chemistry, 1996
- Three-dimensional Structure of Influenza A N9 Neuraminidase and Its Complex with the Inhibitor 2-Deoxy 2,3-Dehydro-N-Acetyl Neuraminic AcidJournal of Molecular Biology, 1993
- Three-dimensional structure of the neuraminidase of influenza virus A/Tokyo/3/67 at 2·2 Å resolutionJournal of Molecular Biology, 1991
- The Behavior and Significance of Slow‐Binding Enzyme InhibitorsPublished by Wiley ,1988
- The slow-binding and slow, tight-binding inhibition of enzyme-catalysed reactionsTrends in Biochemical Sciences, 1982